Esther Rajavelu Sells 25,240 Shares of Spero Therapeutics (NASDAQ:SPRO) Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) insider Esther Rajavelu sold 25,240 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $2.51, for a total transaction of $63,352.40. Following the completion of the transaction, the insider directly owned 986,851 shares of the company’s stock, valued at approximately $2,476,996.01. The trade was a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Esther Rajavelu also recently made the following trade(s):

• On Friday, February 6th, Esther Rajavelu sold 87,917 shares of Spero Therapeutics stock. The stock was sold at an average price of $2.36, for a total value of $207,484.12.

Spero Therapeutics Stock Performance

Shares of NASDAQ:SPRO traded up $0.11 during trading on Wednesday, hitting $2.53. The company’s stock had a trading volume of 617,278 shares, compared to its average volume of 466,746. The company has a market capitalization of $146.49 million, a PE ratio of 21.09 and a beta of 1.43. Spero Therapeutics, Inc. has a fifty-two week low of $0.57 and a fifty-two week high of $3.22. The stock’s 50-day moving average price is $2.51 and its two-hundred day moving average price is $2.41.

Spero Therapeutics (NASDAQ:SPRO) last issued its quarterly earnings data on Thursday, March 26th. The company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.73. Spero Therapeutics had a return on equity of 22.53% and a net margin of 12.83%.The firm had revenue of $41.30 million during the quarter, compared to analyst estimates of $26.00 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Invesco Ltd. bought a new position in Spero Therapeutics during the 2nd quarter worth $43,000. Dimensional Fund Advisors LP acquired a new position in shares of Spero Therapeutics during the third quarter valued at $55,000. Millennium Management LLC acquired a new stake in shares of Spero Therapeutics in the 4th quarter worth about $56,000. Quadrature Capital Ltd bought a new stake in Spero Therapeutics in the 4th quarter valued at about $88,000. Finally, Two Sigma Investments LP acquired a new position in Spero Therapeutics during the 3rd quarter valued at about $93,000. Institutional investors and hedge funds own 25.60% of the company’s stock.

Wall Street Analysts Forecast Growth

SPRO has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Spero Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen raised shares of Spero Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Sunday, March 29th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Reduce”.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical?stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug?resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram?negative pathogens.